Press Releases - Daiichi Sankyo US
WEB5 days ago · About Daiichi Sankyo Daiichi Sankyo is an innovative global healthcare company contributing to the sustainable development of society that discovers, develops and delivers new standards of care to enrich the quality of life around the world. With more than 120 years of experience, Daiichi Sankyo leverages its …
Study: Merck and Daiichi's Lung Cancer Treatment Shows Promise
WEB4 days ago · The sixth ADC candidate is DS-3939, a TA-MUC1-directed ADC, which Daiichi Sankyo is developing on its own. Pfizer PFE also has a strong portfolio of ADC drugs, which were added with last year’s ...
Merck, Daiichi ADC hits goal in phase 3 lung cancer study
WEB4 days ago · A phase 3 trial of Daiichi Sankyo and Merck & Co.’s HER3-directed antibody-drug conjugate (ADC) has hit its primary endpoint, boosting plans to take a second shot at FDA approval. But two more ...
Daiichi Sankyo, Merck's Patritumab Deruxtecan Meets Primary
WEB4 days ago · (RTTNews) - Merck & Co Inc. (MRK) on Tuesday said HERTHENA-Lung02 phase 3 study evaluating Daiichi Sankyo and Merck's patritumab deruxtecan in patients with EGFR-mutated non-small cell lung cancer ...
Daiichi Sankyo-Merck's 'guided-missile' cancer drug meets main …
WEB4 days ago · Sept 17 (Reuters) - Daiichi Sankyo (4568.T), opens new tab and Merck (MRK.N), opens new tab said on Tuesday that their drug, patritumab deruxtecan, met the main goal of extending the time some ...
Merck/Daiichi Sankyo Partnered Lung Cancer Candidate Meets …
WEB4 days ago · MRK. 4568.T. Merck/Daiichi Sankyo Partnered Lung Cancer Candidate Meets Primary Goal In Late-Stage Study. Tuesday, Merck & Co Inc (NYSE: MRK) released topline data from the HERTHENA-Lung02 phase 3 ...
Study: Merck and Daiichi's Lung Cancer Treatment Shows Promise
WEB4 days ago · MRK - Free Report) announced that a phase study evaluating its Daiichi Sankyo-partnered HER3-directed DXd antibody drug conjugate (ADC), patritumab deruxtecan, for treating EGFR-mutated non-small ...
Daiichi Sankyo and MSD’s ADC improves progression-free …
WEBDaiichi Sankyo and MSD (Merck & Co) have reported that the Phase III HERTHENA-Lung02 clinical trial of patritumab deruxtecan, an HER3-directed DXd antibody-drug conjugate (ADC) in patients with ...
WEBSep 15, 2024 · About Daiichi Sankyo Daiichi Sankyo is an innovative global healthcare company contributing to the sustainable development of society that discovers, develops and delivers new standards of care to enrich the quality of life around the world. With more than 120 years of experience, Daiichi Sankyo leverages its world-class science and
Daiichi wants to go it alone in search for targeted cancer drugs
WEB5 days ago · Sep 17, 2024. The Japanese cancer drug powerhouse Daiichi Sankyo has its sights on the next generation of targeted oncology drugs, and this time it might not need a partner to get it over the line ...
- Some results have been removed
Skip to content